论文部分内容阅读
目的讨论血管内皮生长因子(VEGF)与血小板反应素1(TSP-1)在肾上腺皮质肿瘤中的表达及其临床意义。方法选取经手术治疗且取得完整临床资料的肾上腺皮质肿瘤石蜡包埋标本37例,其中良性组20例,恶性组(ACC组)17例。采用免疫组化技术,检测并分析良、恶性肾上腺皮质肿瘤中VEGF和TSP-1的表达情况。结果 TSP-1在ACC组中呈低表达(5/17,29.41%),在良性组中表达高(13/20,65.00%),ACC组与良性组之间TSP-1的表达有显著性差异(P<0.05)。VEGF在ACC组中呈高表达(70.59%),在良性组中表达较低(25.00%),VEGF在ACC组中的表达与在良性组中的表达有显著性差异(P<0.05)。微血管密度(MVD)在ACC组中的表达为(76.40±15.64)/视野,良性组中为(21.05±8.07)/视野,两者之间有显著性差异(P<0.05)。VEGF的表达和MVD呈正相关(P<0.01),TSP-1的表达和MVD呈负相关(P<0.01)。VEGF的表达和TSP-1的表达呈负相关(rs=-0.386)。结论 VEGF与TSP-1表达不平衡可能是肾上腺皮质肿瘤肿瘤性血管生成的重要原因,有望为抗肿瘤靶向治疗在ACC中的应用提供相应的理论依据。
Objective To investigate the expression of vascular endothelial growth factor (VEGF) and thrombospondin-1 (TSP-1) in adrenocortical tumors and its clinical significance. Methods Thirty-seven paraffin-embedded specimens of adrenocortical tumors surgically treated with complete clinical data were selected, of which 20 were benign and 17 were malignant (ACC). Immunohistochemistry was used to detect and analyze the expression of VEGF and TSP-1 in benign and malignant adrenocortical tumors. Results The expression of TSP-1 was significantly lower in ACC group (5 / 17,29.41%) than that in benign group (13/20, 65.00%). The expression of TSP-1 in ACC group was significantly higher than that in benign group Difference (P <0.05). The expression of VEGF in ACC group was high (70.59%), low expression in benign group (25.00%), VEGF expression in ACC group was significantly different from that in benign group (P <0.05). The expression of MVD in ACC group was (76.40 ± 15.64) / visual field and in benign group was (21.05 ± 8.07) / visual field, there was a significant difference between the two groups (P <0.05). The expression of VEGF was positively correlated with MVD (P <0.01). The expression of TSP-1 was negatively correlated with MVD (P <0.01). The expression of VEGF and TSP-1 was negatively correlated (r ¯s = -0.386). Conclusions The imbalance of VEGF and TSP-1 expression may be the important reason of tumor angiogenesis in adrenocortical tumors and is expected to provide a theoretical basis for the application of anti-tumor targeted therapy in ACC.